Viewpoint: Glyphosate herbicide’s ‘tough year’ could get much worse

| | October 9, 2017

Monsanto’s flagship weed killer, Roundup, has had a tough year. And it could get worse.

With Roundup at the center of a federal case in the United States over claims that it causes cancer, European Union officials … weigh whether to allow the continued use of products that contain Roundup’s active ingredient, glyphosate, in its 28 nations.

Because Europe makes such decisions the way Americans vote for president — with a weighted vote among its member states — the outcome is tricky to predict.

A final decision, already long delayed, is not expected until later this year. France and Italy have indicated they will oppose the reauthorization, while Germany’s position remains unclear. A range of outcomes are possible, including phasing out Roundup and similar products entirely or limiting the length of their reapproval.

Related article:  Talking Biotech: 30-year study confirms environmental benefits of glyphosate use

While Roundup still enjoys broad support among farmers and a number of European governments, sentiment against its maker is at a low point in Europe, with a petition campaign against glyphosate reportedly surpassing one million signatures.

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion and analysis. Read full, original post: Monsanto’s Roundup Faces European Politics and U.S. Lawsuits


The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.


News on human & agricultural genetics and biotechnology delivered to your inbox.

Send this to a friend